Evolus Inc (EOLS) Stock Price, Quote & News

Company Profile

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 949 284 4555

Website: www.evolus.com

Address:

520 Newport Center Drive, Suite 1200, Newport Beach, United States

d_risk May. 5 at 3:47 PM

$EOLS - Evolus Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +78.0% above peer average (21,403 vs 12,026 across 652 peers). Evolus’ 10-Q flags mounting pressure on a loss-making, cash-pay aesthetics model: intensified neurotoxin/HA competition vs AbbVie/Galderma, new macro/tariff and Medytox royalty headwinds, heavy reliance on sole foreign licensors and digital/AI systems, expanded global regulatory/IP and data/privacy risk, plus heightened talent, financing, governance and stock-volatility concerns. 🟢 Added 🟠 Removed https://d-risk.ai/EOLS/10-Q/2026-05-04

0 · Reply

ItsAllAboutBeingFirst May. 5 at 2:30 PM

$EOLS is great for the space and great for $AIRS - the space is a coming back..

0 · Reply

Finitemaf May. 4 at 10:09 PM

$EOLS

0 · Reply

HellenJune May. 4 at 9:24 PM

$EOLS What's the deal?

0 · Reply

StocktwitsEarnings May. 4 at 8:13 PM

$EOLS Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.16 up 46.67% YoY • Reported revenue of $73.14M up 6.74% YoY • Evolus reaffirms full-year 2026 net revenue guidance of $327M to $337M and non-GAAP operating expenses of $210M to $216M, expecting a low- to mid-single digit Adjusted EBITDA margin.

0 · Reply

AlertsAndNews May. 4 at 8:07 PM

$EOLS some volume here Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

0 · Reply

Finitemaf Apr. 30 at 12:07 AM

$EOLS how are we feeling about earnings here? Debating adding to swing trade earnings

0 · Reply

BillionerOfKing Apr. 29 at 4:21 PM

$EOLS Current Stock Price: $5.14 Contracts to trade: $5.0 EOLS May 15 2026 Call Entry: $0.40 Exit: $0.51 ROI: 29% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Mandi63 Apr. 16 at 4:50 PM

$EOLS $15.50 price target

0 · Reply

buymoremakemore Apr. 14 at 11:18 PM

$EOLS Bought 5k shares here. H2 going to be rewarding!

0 · Reply

Evolus announces commercial launch of Estyme in Europe

May 11, 2026, 8:30 AM EDT - 2 days ago

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

May 4, 2026, 4:30 PM EDT - 8 days ago

Evolus Earnings Call Transcript: Q1 2026

2026-05-04T20:13:04.000Z - 8 days ago

Evolus reports Q1 EPS (16c), consensus (12c)

May 4, 2026, 4:05 PM EDT - 8 days ago

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

May 4, 2026, 11:16 AM EDT - 8 days ago

Weight-loss revolution sparks new appetite for aesthetics firms

APYX ESTA INMD

Apr 14, 2026, 3:45 PM EDT - 4 weeks ago

Evolus Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 8:30 AM EDT - 4 weeks ago

Evolus to Report First Quarter Financial Results on May 4, 2026

Mar 31, 2026, 8:00 AM EDT - 6 weeks ago

Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference

Mar 20, 2026, 4:05 PM EDT - 7 weeks ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 11, 2026, 11:20 AM EDT - 2 months ago

Evolus Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 4:30 PM EST - 2 months ago

Evolus Earnings Call Transcript: Q4 2025

2026-03-03T21:21:20.000Z - 2 months ago

Evolus sees FY26 revenue $327M-$337M, consensus $329.66M

2026-03-03T21:10:39.000Z - 2 months ago

Evolus reports Q4 EPS 0c, consensus 4c

Mar 3, 2026, 4:05 PM EST - 2 months ago

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026

Feb 25, 2026, 8:00 AM EST - 2 months ago

Evolus to Participate in The Leerink Partners Global Healthcare Conference

Feb 17, 2026, 8:00 AM EST - 3 months ago

Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026

2026-02-04T12:36:31.000Z - 3 months ago

Evolus price target lowered to $15 from $19 at Mizuho

2026-01-22T12:21:40.000Z - 3 months ago

Evolus price target lowered to $13 from $18 at BTIG

2026-01-13T12:16:01.000Z - 4 months ago

Evolus price target lowered to $17 from $20 at Stifel

2026-01-09T13:52:35.000Z - 4 months ago

Evolus narrows FY25 revenue view to $295.5M-$297.5M from $295M-$305M

2026-01-09T13:52:00.000Z - 4 months ago

Evolus sees FY26 revenue $327M-$337M, consensus $351.66M

2026-01-09T13:45:31.000Z - 4 months ago

Evolus sees Q4 revenue $88.6M-$90.6M, consensus $90.91M

Jan 9, 2026, 8:30 AM EST - 4 months ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

2025-12-02T12:15:41.000Z - 5 months ago

Evolus price target lowered to $19 from $20 at Mizuho

Nov 11, 2025, 11:20 AM EST - 6 months ago

Evolus Transcript: Stifel 2025 Healthcare Conference

2025-11-06T12:26:52.000Z - 6 months ago

Evolus price target raised to $20 from $19 at Mizuho

2025-11-05T21:33:24.000Z - 6 months ago

Evolus sees FY25 revenue $295M-$305M, consensus $296.03M

Nov 5, 2025, 4:30 PM EST - 6 months ago

Evolus Earnings Call Transcript: Q3 2025

2025-11-05T21:25:49.000Z - 6 months ago

Evolus reports Q3 EPS (24c), consensus (18c)

Nov 5, 2025, 4:05 PM EST - 6 months ago

Evolus Reports Third Quarter 2025 Financial Results

Oct 28, 2025, 8:00 AM EDT - 7 months ago

Evolus to Participate in 2025 Stifel Healthcare Conference

Oct 22, 2025, 8:00 AM EDT - 7 months ago

Evolus to Report Third Quarter Financial Results on November 5, 2025

Sep 22, 2025, 9:03 AM EDT - 8 months ago

Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch

Sep 12, 2025, 5:30 PM EDT - 8 months ago

Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2025-09-08T13:00:18.000Z - 8 months ago

Evolus appoints Tatjana Mitchell as CFO

Sep 8, 2025, 8:30 AM EDT - 8 months ago

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

2025-08-25T12:15:59.000Z - 9 months ago

Evolus announces Evolysse Sculpt trial meets primary endpoint

Aug 25, 2025, 8:00 AM EDT - 9 months ago

Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

Aug 20, 2025, 8:00 AM EDT - 9 months ago

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product

Aug 5, 2025, 4:30 PM EDT - 10 months ago

Evolus Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:05 PM EDT - 10 months ago

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 31, 2025, 8:05 AM EDT - 10 months ago

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

Jul 22, 2025, 8:05 AM EDT - 10 months ago

Evolus to Report Second Quarter Financial Results on August 5, 2025

Jul 9, 2025, 8:00 AM EDT - 11 months ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Evolysse™ Recognized in 2025 Shape Skin Awards

May 27, 2025, 4:15 PM EDT - 1 year ago

Evolus Announces Departure of its Chief Financial Officer

May 22, 2025, 8:00 AM EDT - 1 year ago

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

May 7, 2025, 4:30 PM EDT - 1 year ago

Evolus Earnings Call Transcript: Q1 2025

May 7, 2025, 4:05 PM EDT - 1 year ago

Evolus Reports First Quarter 2025 Results

May 5, 2025, 4:05 PM EDT - 1 year ago

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Evolus to Report First Quarter Financial Results on May 7, 2025

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Evolus Announces Commercial Launch of Evolysse™

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

Apr 8, 2025, 12:45 PM EDT - 1 year ago

Evolus Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Mar 12, 2025, 3:30 PM EDT - 1 year ago

Evolus Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 9:20 AM EDT - 1 year ago

Evolus Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 4:30 PM EST - 1 year ago

Evolus Earnings Call Transcript: Q4 2024

Mar 4, 2025, 4:17 PM EST - 1 year ago

Evolus posts quarterly profit on strong sales of cosmetic injection

Mar 4, 2025, 4:05 PM EST - 1 year ago

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Feb 27, 2025, 8:00 AM EST - 1 year ago

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Feb 20, 2025, 8:00 AM EST - 1 year ago

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Feb 18, 2025, 8:00 AM EST - 1 year ago

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Feb 13, 2025, 1:45 PM EST - 1 year ago

US FDA approves Evolus' anti-wrinkle gels

Feb 13, 2025, 1:30 PM EST - 1 year ago

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Jan 21, 2025, 8:00 AM EST - 1 year ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

Nov 19, 2024, 10:55 AM EST - 1 year ago

Evolus Transcript: Stifel 2024 Healthcare Conference

Nov 6, 2024, 4:30 PM EST - 1 year ago

Evolus Earnings Call Transcript: Q3 2024

Nov 6, 2024, 4:05 PM EST - 1 year ago

Evolus Reports Third Quarter 2024 Results

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Evolus to Participate in Stifel 2024 Healthcare Conference

Oct 31, 2024, 2:02 PM EDT - 1 year ago

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Evolus to Report Third Quarter Financial Results on November 6, 2024

Sep 12, 2024, 8:00 AM EDT - 1 year ago

Evolus Transcript: Investor Day 2024

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Aug 13, 2024, 12:30 PM EDT - 1 year ago

Evolus Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Jul 31, 2024, 4:30 PM EDT - 1 year ago

Evolus Earnings Call Transcript: Q2 2024

Jul 31, 2024, 4:09 PM EDT - 1 year ago

Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Evolus to Hold Investor Day on September 12, 2024

Jul 30, 2024, 8:00 AM EDT - 1 year ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

d_risk May. 5 at 3:47 PM

0 · Reply

ItsAllAboutBeingFirst May. 5 at 2:30 PM

$EOLS is great for the space and great for $AIRS - the space is a coming back..

0 · Reply

Finitemaf May. 4 at 10:09 PM

$EOLS

0 · Reply

HellenJune May. 4 at 9:24 PM

$EOLS What's the deal?

0 · Reply

StocktwitsEarnings May. 4 at 8:13 PM

0 · Reply

AlertsAndNews May. 4 at 8:07 PM

$EOLS some volume here Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

0 · Reply

Finitemaf Apr. 30 at 12:07 AM

$EOLS how are we feeling about earnings here? Debating adding to swing trade earnings

0 · Reply

BillionerOfKing Apr. 29 at 4:21 PM

0 · Reply

Mandi63 Apr. 16 at 4:50 PM

$EOLS $15.50 price target

0 · Reply

buymoremakemore Apr. 14 at 11:18 PM

$EOLS Bought 5k shares here. H2 going to be rewarding!

0 · Reply

Mandi63 Apr. 7 at 6:33 AM

$EOLS 90 MILLION EVERY 3 MONTHS . Most companies dream of this success…Price target $15.50

2 · Reply

Arcides Apr. 7 at 3:54 AM

$EOLS shorts dream...what a piece of shit this stock has being.

0 · Reply

Mandi63 Apr. 2 at 11:40 AM

$EOLS price target $15.50

0 · Reply

lknite Mar. 30 at 8:23 PM

$EOLS ouch

1 · Reply

Bohrenn Mar. 26 at 11:55 AM

$WVE , $EOLS, $BEAM - mit dem Sharedeals.de No Brainer Club ist eines sicher: manchmal ein Schritt vor (denn die Flut hebt alle Boote), aber häufig 3 Schritte zurück. In Summe verliert man mit der Aktienauswahl vor allem verlässlich Geld.

0 · Reply